Itch from chronic kidney disease can dominate dialysis days even when phosphorus binders and antihistamines already failed. Korsuva (difelikefalin) is a selective kappa-opioid receptor agonist peptide given into the dialysis circuit at the end of hemodialysis for moderate-to-severe CKD-associated pruritus in adults. The everyday takeaway is fall-and-alertness planning after treatment—not a PTH or calcium drug, and not a home itch cream substitute.
What the label covers on the dialysis chair
MedlinePlus explains hemodialysis as blood cleaned through a machine several times a week. Korsuva is labeled only for adults on hemodialysis; it has not been studied in peritoneal dialysis and is not recommended there. The medicine is administered by clinic staff as an intravenous bolus into the venous line of the dialysis circuit when that session ends—patients do not take it home as a bottle of pills.
UniProt lists prodynorphin (P01213), the precursor of dynorphin peptides that act at kappa-opioid receptors. Difelikefalin is designed to engage that peripheral itch pathway without being a classic mu-opioid painkiller. That is a different biology from calcimimetics that lower PTH on dialysis.
Dizziness, falls, driving, and medicine overlaps
The DailyMed label warns that dizziness, somnolence, mental-status changes, and gait problems—including falls—have occurred. Sedating antihistamines, other centrally acting depressants, and opioid pain medicines can add to that risk, so bring a full medication list to the dialysis team before starts or changes. The label also cautions about driving and operating machinery until you know how you feel after treatments.
MedlinePlus covers general itch causes and care, which still matter: dry skin care, reviewing new detergents, and asking whether another systemic disease is contributing. Korsuva does not replace evaluation for infection, allergy, or liver disease when those clues appear. Missed dialysis sessions mean missed in-center doses—ask how the unit reschedules rather than improvising.
Questions that change what you notice next. Before the first in-center dose, write down which itch medicines you already use, whether you have fallen recently, and whether you drive yourself home from dialysis. Ask who will watch you after the bolus if you feel lightheaded, how to report new confusion or unsteady walking, and whether any sleeping pills or antihistamines should be paused on dialysis days. Carry a note that Korsuva is a kappa-opioid itch medicine given at hemodialysis—not a PTH-lowering dialysis drug—so covering clinicians do not confuse it with Parsabiv or similar calcium/PTH therapies.
Not medical advice.
Sources
- DailyMed: Korsuva (difelikefalin) prescribing information
- MedlinePlus: Dialysis
- MedlinePlus: Itching
- UniProt: Prodynorphin (P01213)
Related reading
- Parsabiv dialysis PTH and calcium watches
- Regranex diabetic foot ulcer cancer warning
- Oritavancin clotting lab interference after infusion
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-10 PT. Not medical advice.